2 Under-the-Radar Stocks to Buy and Hold
That's all the more surprising considering the therapy is under accelerated approval, meaning it will have to show effectiveness in confirmatory trials or be taken off the market. The strong prescribing trends for Rezdiffra so far suggest that physicians are confident it's at least somewhat effective -- otherwise, even with FDA approval, they would be less likely to prescribe it.
Rezdiffra's trajectory to date also underscores the significant unmet need in MASH, an area that several pharmaceutical leaders are trying to break into. According to some estimates, about 22 million adults in the U.S. have MASH, while about 9 million of them have clinically meaningful liver disease as a result. So far, Madrigal has treated about 36,250 patients; that number is only 17% of the company's target of 315,000 patients who are seeing specialists.
Besides Rezdiffra, Madrigal has over 10 programs in its MASH pipeline. It will likely seek to target patients even beyond the 315,000 it initially set its eyes on. Madrigal Pharmaceuticals could ride this market for years, delivering strong financial results and competitive returns.
Should you buy stock in Axsome Therapeutics right now?
Before you buy stock in Axsome Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Axsome Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $530,233!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,119,682!*
Now, it’s worth noting Stock Advisor’s total average return is 955% — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 10, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics. The Motley Fool has a disclosure policy.
2 Under-the-Radar Stocks to Buy and Hold was originally published by The Motley Fool
Content Original Link:
" target="_blank">
